Brief: Enlivex Therapeutics Announces New Analyses From Recently Completed Phase Ib Clinical Trial Of Allocetra In Patients With Sepsis
28/05/2020 13:36
May 28 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX THERAPEUTICS LTD - ANNOUNCED NEW ANALYSES FROM ITS
RECENTLY COMPLETED PHASE IB CLINICAL TRIAL OF ALLOCETRA IN
PATIENTS WITH SEPSIS
Source text for Eikon: ID:nGNX5mSdpm
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment